Craft

Medivir

Stock Price

KR7

2023-07-17

Market Capitalization

KR402.3 M

2023-07-17

Revenue

KR7.6 M

FY, 2023

Medivir Summary

Company Summary

Overview
Medivir researches, develops, and sells pharmaceuticals primarily for the treatment of oncology. The Company's products portfolio includes Remetinostat for use in the treatment of cutaneous T-cell lymphoma; Birinapant in combination with Keytrudafor treating solid tumors; and MIV-711 for the treatment of osteoarthritis, as well as MIV-818, a preclinical stage nucleoside pro-drug for treating patients with advanced liver cancers. Its products also include drugs for the treatment of labial herpes and hepatitis C virus.
Type
Public
Status
Active
Founded
1988
HQ
Huddinge, SE | view all locations
Website
http://www.medivir.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Helena Levander

    Helena Levander, Chairman of the Board

    • Magnus Christensen

      Magnus Christensen, Chief Financial Officer

      • Uli Hacksell

        Uli Hacksell, Board Member

        • Fredrik Öberg

          Fredrik Öberg, Chief Scientific Officer

          LocationsView all

          1 location detected

          • Huddinge, Stockholms län HQ

            Sweden

            Box 1086 Lunastigen 7

          Medivir Financials

          Summary Financials

          Revenue (Q2, 2024)
          kr1.1M
          Gross profit (Q2, 2024)
          kr1.3M
          Net income (Q2, 2024)
          (kr35.9M)
          Cash (Q2, 2024)
          kr9.6M
          EBIT (Q2, 2024)
          (kr37.3M)
          Enterprise value
          $402.8M

          Footer menu